BioSpace News Archive

Enveric Biosciences today announced it has been included in the new AdvisorShares Psychedelics ETF, trading under the ticker symbol “PSIL” on the NYSE Arca exchange.

Bicara Therapeutics today announced that company leadership will participate in two upcoming virtual investor conferences in November: Stifel 2021 Virtual Healthcare Conference Format: Live presentation Date: Monday, November 15, 2021 Time: 10:40

Oncology Pharma, Inc. is pleased to provide some insight into the progress of its co-development project with NanoSmart Pharmaceuticals, Inc. for the development of a lead cancer drug candidate.

Some of the prominent players operating in the global market for nanoemulsion are Mitsubishi Tanabe Pharma Corporation, GlaxoSmithKline plc, Sanofi, Novartis AG, AbbVie Inc., Allergan plc, AstraZeneca Inc., Kaken Pharmaceutical Co., Ltd., Fresenius Kabi AG, and B. Braun Melsungen AG.

The global Medical Engineered Materials Market is being driven by increased investments in healthcare and an increasing ageing population in Latin America, the Middle East and Africa, and Asia Pacific, as well as a growing desire for improvement in healthcare settings.

The body contouring devices market has been anticipated to experience significant growth avenues in the forthcoming years.

Masimo announced the findings of a prospective study published in Frontiers in Aging Neuroscience in which Dr. Shuyi Yang and colleagues at Capital Medical University in Beijing investigated whether Masimo Root® with a multimodal brain monitoring algorithm to manage anesthesia during spinal surgery could improve postoperative cognitive function.

AlgoTherapeutix is a European Biotech developing ATX01, a non-opioid topical treatment for Peripheral Neuropathic Pain.

Azurity Pharmaceuticals, Inc. a private specialty pharmaceutical company focused on developing innovative products to meet the unique needs of patients with underserved conditions, announced the U.S. Food and Drug Administration approval of EPRONTIA™ oral solution, 25 mg/mL.

Bolt Biotherapeutics (Nasdaq: BOLT), today announced that Randall C. Schatzman, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16, 2021 at 1:00 p.m. PT (4:00 p.m. ET).